Skip to content

Orexo announces new partner for the commercialization of Zubsolv® in the United States.

Uppsala, Sweden – May 20, 2014 – Orexo AB announces a new partnership between Orexo US, Inc. and inVentiv Health for the commercialization of Zubsolv in the US. The new partnership agreement replaces existing contracts and will become effective July 1st, 2014 and has a three year term.

In the new partnership, Orexo takes the leadership and control of all commercial functions to ensure the efficient and agile governance of the commercialization of Zubsolv. Consequently Orexo will directly employ the sales managers and take over leadership and day to day management of field-based promotional activities. The new partner inVentiv Health will take responsibility of employing and supporting the individual sales representatives.

The new partnership calls for Orexo to cover direct sales force expenses from inVentiv Health. As a consequence of the new partnership structure the expenses for the sales organization will be reported as a selling expense from the second quarter this year. There will be a limited one-time transition expense reported in the second quarter, associated with the change of partner. From the third quarter 2014, there will be no further expenses related to the previous partnership.

“With this new partnership structure Orexo will increase the control of the sales operations to ensure Zubsolv gains the attention and focus required to maximize the potential. With the new structure in place we will be able to act much more swiftly in the market and we see this as a natural next step in the evolution of Orexo and an important driver of growth” says Nikolaj Sørensen, Chief Executive Officer of Orexo AB.

For further information, please contact:
Nikolaj Sorensen, President and CEO
Tel: +46 (0)703-50 78 88, E-mail:

Henrik Juuel, EVP and CFO
Tel: +46 (0)722-20 94 77, E-mail:

About Orexo AB
Orexo AB is a specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. The company is commercializing its proprietary product, ZUBSOLV® (buprenorphine and naloxone), in the United States for maintenance treatment of opioid dependence. ZUBSOLV is a novel sublingual formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the EU, US and Japan. Orexo’s development expertise is within the area of reformulation technologies, and especially sublingual formulations. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.

Source: Orexo